Novartis Myeloma Drug Shows Early Promise in Key Trial
Insights - An experimental drug from Novartis (NVS) designed to treat a bone marrow cancer met its primary goal in a phase 3 study. In an earlier … Continue Reading
Read nowSearch Results for gene therapy
Depression Drug Failure Sets Eli Lilly Back
Insights - Eli Lilly and Company (LLY) on Thursday said it would not seek approval for edivoxetine, an experimental drug to treat major depression, after it failed … Continue Reading
Read now
Threshold Pharmaceuticals’ Early Data on TH-302 for Glioblastoma
Insights - Threshold Pharmaceuticals (THLD) on Friday announced early data from the Phase 1 portion of an investigator-sponsored Phase 1/2 trial of its investigational hypoxia-targeted drug TH-302 … Continue Reading
Read now
Forest Scores an Incomplete Grade for Cariprazine
Insights - Forest Laboratories Inc. (FRX) and Gedeon Richter Plc. announced that the U.S. Federal Drug Administration (FDA) issued a complete response letter regarding the New Drug … Continue Reading
Read now
Amgen’s PCSK9 Inhibitor Beneficial to Cholesterol Levels
Insights - Amgen’s (AMGN) PCSK9 inhibitor evolucumab (AMG145), when added to standard treatments, helped 86% of patients get their LDL cholesterol levels to a target of 100 … Continue Reading
Read now
This Antibiotic Play May Be the Trius of 2014
Research - 2013 has been a year of change in the landscape for publicly traded antibiotic developers, driven by Cubist Pharmaceuticals’ (CBST) high-profile acquisitions of competitors Trius … Continue Reading
Read now
NPS Pharmaceuticals: Guidance Raised but Shares Lag
Insights - NPS Pharmaceuticals (NPSP) shares traded down 14% on Wednesday, despite reporting strong third quarter results and raising guidance for 2013. The weakness appears to stem … Continue Reading
Read now